The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027, which includes Novo Nordisk's blockbuster weight-loss drug Wegovy. Here's

Trump added Denmark to his growing list of tariff targets — including Canada, Mexico and China — as he has increasingly spoken of the U.S. taking Greenland off Denmark’s hands. Danish multinational pharmaceutical giant Novo Nordisk is the sole owner ...

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.

Mads Krogsgaard Thomsen, CEO of Novo Nordisk Foundation, discusses European competitiveness.

(Reuters) - European shares were subdued on Tuesday, as rising financials and healthcare shares countered broader losses stemming from uncertainty related to U.S. President Donald Trump's proposed tariff measures following his inauguration. The pan-European STOXX 600 was up 0.1% as of 0954 GMT, hovering near its highest in three months.

By Nikhil Sharma and Pranav Kashyap (Reuters) -European shares rose on Tuesday, buoyed by gains in the healthcare and luxury sectors, but the uptick was tempered by lingering uncertainties over U.S. President Donald Trump's proposed tariff measures following his inauguration.

Denmark is the leading supplier of hearing aids to the U.S., per The Times, and is home to Novo Nordisk, the maker of ... wants 25% tariffs on imports from Mexico and Canada and an additional ...

Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's largest healthcare company, with a market cap that topped $8

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

European shares held steady with slight gains in financials and healthcare despite global uncertainties over U.S. President Donald Trump's proposed tariffs. The market's cautious optimism was challenged by pressure on automakers and basic resources.

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.

European markets were subdued on Tuesday, with the STOXX 600 up 0.1 percent as healthcare and financials gains offset losses in automakers and renewable energy. Trump’s delay on new tariffs offered relief,